Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences: The insulin delivery system rating questionnaire

Mark Peyrot, Richard R. Rubin

    Research output: Contribution to journalArticle

    Abstract

    OBJECTIVE - To provide a preliminary assessment of the validity and reliability of a new measure of health-related quality of life (HRQOL) and treatment preference for insulin delivery systems. RESEARCH DESIGN AND METHODS - Study participants were 197 adults with type 1 or type 2 diabetes who completed the Insulin Delivery System Rating Questionnaire (IDSRQ), a self-administered questionnaire developed for this study. The IDSRQ assessed patient perceptions of treatment satisfaction, impact of treatment on daily activities, clinical efficacy, diabetes-related worries and social burdens, psychological well-being, and overall treatment system preference of patients using continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI). RESULTS - The IDSRQ subscales had acceptable reliability (α = 0.67-0.92, median 0.82) and test-retest correlations (intraclass correlation coefficient 0.67-0.94, median 0.88). Floor effects (0-10%, median 0%) and ceiling effects (0-18%, median 4%) were minimal. There were statistically significant differences (P <0.05) between patients using CSII and MDI on all IDSRQ subscales except psychological well-being (P = 0.096); differences in means were 0.3-1.4 SD units (median 0.9). Multiple regression analysis (controlling for age, sex, and type of diabetes) showed that treatment satisfaction, perceived clinical efficacy, and independently associated with overall treatment preference and accounted for half of the difference in preference between CSII and MDI patients. CONCLUSIONS - Preliminary' findings suggest that the IDSRQ is a valid and reliable measure of HRQOL and treatment preferences for insulin delivery systems. The subscales are comprehensive, sensitive to differences in user populations, and account for most of the preference for a particular insulin delivery system.

    Original languageEnglish (US)
    Pages (from-to)53-58
    Number of pages6
    JournalDiabetes Care
    Volume28
    Issue number1
    DOIs
    StatePublished - Jan 2005

    Fingerprint

    Reproducibility of Results
    Quality of Life
    Insulin
    Subcutaneous Infusions
    Therapeutics
    Injections
    Surveys and Questionnaires
    Psychology
    Patient Preference
    Type 2 Diabetes Mellitus
    Research Design
    Regression Analysis

    ASJC Scopus subject areas

    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism

    Cite this

    Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences : The insulin delivery system rating questionnaire. / Peyrot, Mark; Rubin, Richard R.

    In: Diabetes Care, Vol. 28, No. 1, 01.2005, p. 53-58.

    Research output: Contribution to journalArticle

    @article{6175056bc60a4ad69064ded095063030,
    title = "Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences: The insulin delivery system rating questionnaire",
    abstract = "OBJECTIVE - To provide a preliminary assessment of the validity and reliability of a new measure of health-related quality of life (HRQOL) and treatment preference for insulin delivery systems. RESEARCH DESIGN AND METHODS - Study participants were 197 adults with type 1 or type 2 diabetes who completed the Insulin Delivery System Rating Questionnaire (IDSRQ), a self-administered questionnaire developed for this study. The IDSRQ assessed patient perceptions of treatment satisfaction, impact of treatment on daily activities, clinical efficacy, diabetes-related worries and social burdens, psychological well-being, and overall treatment system preference of patients using continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI). RESULTS - The IDSRQ subscales had acceptable reliability (α = 0.67-0.92, median 0.82) and test-retest correlations (intraclass correlation coefficient 0.67-0.94, median 0.88). Floor effects (0-10{\%}, median 0{\%}) and ceiling effects (0-18{\%}, median 4{\%}) were minimal. There were statistically significant differences (P <0.05) between patients using CSII and MDI on all IDSRQ subscales except psychological well-being (P = 0.096); differences in means were 0.3-1.4 SD units (median 0.9). Multiple regression analysis (controlling for age, sex, and type of diabetes) showed that treatment satisfaction, perceived clinical efficacy, and independently associated with overall treatment preference and accounted for half of the difference in preference between CSII and MDI patients. CONCLUSIONS - Preliminary' findings suggest that the IDSRQ is a valid and reliable measure of HRQOL and treatment preferences for insulin delivery systems. The subscales are comprehensive, sensitive to differences in user populations, and account for most of the preference for a particular insulin delivery system.",
    author = "Mark Peyrot and Rubin, {Richard R.}",
    year = "2005",
    month = "1",
    doi = "10.2337/diacare.28.1.53",
    language = "English (US)",
    volume = "28",
    pages = "53--58",
    journal = "Diabetes Care",
    issn = "1935-5548",
    publisher = "American Diabetes Association Inc.",
    number = "1",

    }

    TY - JOUR

    T1 - Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences

    T2 - The insulin delivery system rating questionnaire

    AU - Peyrot, Mark

    AU - Rubin, Richard R.

    PY - 2005/1

    Y1 - 2005/1

    N2 - OBJECTIVE - To provide a preliminary assessment of the validity and reliability of a new measure of health-related quality of life (HRQOL) and treatment preference for insulin delivery systems. RESEARCH DESIGN AND METHODS - Study participants were 197 adults with type 1 or type 2 diabetes who completed the Insulin Delivery System Rating Questionnaire (IDSRQ), a self-administered questionnaire developed for this study. The IDSRQ assessed patient perceptions of treatment satisfaction, impact of treatment on daily activities, clinical efficacy, diabetes-related worries and social burdens, psychological well-being, and overall treatment system preference of patients using continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI). RESULTS - The IDSRQ subscales had acceptable reliability (α = 0.67-0.92, median 0.82) and test-retest correlations (intraclass correlation coefficient 0.67-0.94, median 0.88). Floor effects (0-10%, median 0%) and ceiling effects (0-18%, median 4%) were minimal. There were statistically significant differences (P <0.05) between patients using CSII and MDI on all IDSRQ subscales except psychological well-being (P = 0.096); differences in means were 0.3-1.4 SD units (median 0.9). Multiple regression analysis (controlling for age, sex, and type of diabetes) showed that treatment satisfaction, perceived clinical efficacy, and independently associated with overall treatment preference and accounted for half of the difference in preference between CSII and MDI patients. CONCLUSIONS - Preliminary' findings suggest that the IDSRQ is a valid and reliable measure of HRQOL and treatment preferences for insulin delivery systems. The subscales are comprehensive, sensitive to differences in user populations, and account for most of the preference for a particular insulin delivery system.

    AB - OBJECTIVE - To provide a preliminary assessment of the validity and reliability of a new measure of health-related quality of life (HRQOL) and treatment preference for insulin delivery systems. RESEARCH DESIGN AND METHODS - Study participants were 197 adults with type 1 or type 2 diabetes who completed the Insulin Delivery System Rating Questionnaire (IDSRQ), a self-administered questionnaire developed for this study. The IDSRQ assessed patient perceptions of treatment satisfaction, impact of treatment on daily activities, clinical efficacy, diabetes-related worries and social burdens, psychological well-being, and overall treatment system preference of patients using continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI). RESULTS - The IDSRQ subscales had acceptable reliability (α = 0.67-0.92, median 0.82) and test-retest correlations (intraclass correlation coefficient 0.67-0.94, median 0.88). Floor effects (0-10%, median 0%) and ceiling effects (0-18%, median 4%) were minimal. There were statistically significant differences (P <0.05) between patients using CSII and MDI on all IDSRQ subscales except psychological well-being (P = 0.096); differences in means were 0.3-1.4 SD units (median 0.9). Multiple regression analysis (controlling for age, sex, and type of diabetes) showed that treatment satisfaction, perceived clinical efficacy, and independently associated with overall treatment preference and accounted for half of the difference in preference between CSII and MDI patients. CONCLUSIONS - Preliminary' findings suggest that the IDSRQ is a valid and reliable measure of HRQOL and treatment preferences for insulin delivery systems. The subscales are comprehensive, sensitive to differences in user populations, and account for most of the preference for a particular insulin delivery system.

    UR - http://www.scopus.com/inward/record.url?scp=11844280839&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=11844280839&partnerID=8YFLogxK

    U2 - 10.2337/diacare.28.1.53

    DO - 10.2337/diacare.28.1.53

    M3 - Article

    C2 - 15616233

    AN - SCOPUS:11844280839

    VL - 28

    SP - 53

    EP - 58

    JO - Diabetes Care

    JF - Diabetes Care

    SN - 1935-5548

    IS - 1

    ER -